Sierra Oncology Inc (SRRA) Stock Analyst Ratings
USA - NASDAQ:SRRA - US82640U4040 - Common Stock
54.99
+0.02 (+0.04%)
54.99
0 (0%)
ChartMill assigns a Buy % Consensus number of 76% to SRRA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 56.1. This target is 2.02% above the current price.
SRRA was analyzed by 10 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about SRRA.
In the previous month the buy percentage consensus was at a similar level.
SRRA was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-04-14 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-04-14 | Jefferies | Downgrade | Buy -> Hold |
| 2022-04-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-01-31 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-30 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-11-05 | HC Wainwright & Co. | Maintains | Buy |
| 2021-09-27 | Cantor Fitzgerald | Initiate | Overweight |
Sierra Oncology Inc / SRRA FAQ
Can you provide the average price target for Sierra Oncology Inc stock?
10 analysts have analysed SRRA and the average price target is 56.1 null. This implies a price increase of 2.02% is expected in the next year compared to the current price of 54.99.
What is the consensus rating for Sierra Oncology Inc (SRRA) stock?
The consensus rating for Sierra Oncology Inc (SRRA) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for SRRA stock?
The number of analysts covering Sierra Oncology Inc (SRRA) is 10.